EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5- a ]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication

Han Wee Ong iD, Xuan Yang, Jeffery L Smith, Rebekah J Dickmander, Jason W Brown, Tammy M Havener iD, Sharon Taft-Benz, Stefanie Howell, Marcia K Sanders, Jacob L Capener, Rafael M Couñago iD, Edcon Chang iD und 6 weitere

Journal of Medicinal Chemistry · 25.07.2024 · 67 (14) · 12261-12313

DOI: 10.1021/acs.jmedchem.4c00962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.07.2024. Verfasst von Han Wee Ong und 17 weiteren Autor:innen. Beteiligte Einrichtung: Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina 27599, United States. Hauptthemen laut MEDLINE: Triazoles, Pyrimidines, Antiviral Agents, Virus Replication. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIDDK NIH HHS, North Carolina General Assembly.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pyrazolo[1,5-a]pyrimidine scaffold is a promising scaffold to develop potent and selective CSNK2 inhibitors with antiviral activity against β-coronaviruses. Herein, we describe the discovery of a 1,2,4-triazole group to substitute a key amide group for CSNK2 binding present in many potent pyrazolo[1,5-a]pyrimidine inhibitors. Crystallographic evidence demonstrates that the 1,2,4-triazole replaces the amide in forming key hydrogen bonds with Lys68 and a water molecule buried in the ATP-binding pocket. This isosteric replacement improves potency and metabolic stability at a cost of solubility. Optimization for potency, solubility, and metabolic stability led to the discovery of the potent and selective CSNK2 inhibitor 53. Despite excellent in vitro metabolic stability, rapid decline in plasma concentration of 53 in vivo was observed and may be attributed to lung accumulation, although in vivo pharmacological effect was not observed. Further optimization of this novel chemotype may validate CSNK2 as an antiviral target in vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesPyrimidinesAntiviral AgentsVirus ReplicationCasein Kinase IIAnimalsHumansPyrazolesProtein Kinase InhibitorsAmidesStructure-Activity RelationshipMiceRatsSARS-CoV-2Drug DiscoveryMale

Substanzen

TriazolesPyrimidinesAntiviral AgentsCasein Kinase II1,2,4-triazolePyrazolesProtein Kinase InhibitorsAmidespyrazolo(1,5-a)pyrimidine

Autor:innen und Institutionen

  • Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina 27599, United States.
  • Structural Genomics Consortium (SGC) and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
  • Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
  • Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
  • Takeda Development Center Americas, Inc., San Diego, California 92121, United States.

ORCID-Profile: Han Wee Ong, Tammy M Havener, Rafael M Couñago, Edcon Chang, Alison D Axtman, David H Drewry, Timothy M Willson

Förderung

  • NIH HHS
  • NIDDK NIH HHS
  • North Carolina General Assembly
  • Takeda Pharmaceutical Company
  • University of North Carolina
  • North Carolina Biotechnology Center
  • U.S. Department of Defense
  • NIH Illuminating the Druggable Genome

Zitieren

APA

Ong, H. W., Yang, X., Smith, J. L., Dickmander, R. J., Brown, J. W., Havener, T. M., Taft-Benz, S., Howell, S., Sanders, M. K., Capener, J. L., Couñago, R. M., Chang, E., Krämer, A., Moorman, N. J., Heise, M., Axtman, A. D., Drewry, D. H., & Willson, T. M. (2024). More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5- a ]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication. Journal of Medicinal Chemistry, 67(14), 12261-12313. https://doi.org/10.1021/acs.jmedchem.4c00962

Vancouver

Ong HW, Yang X, Smith JL, Dickmander RJ, Brown JW, Havener TM, et al. More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5- a ]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication. Journal of Medicinal Chemistry. 2024;67(14):12261-12313. doi:10.1021/acs.jmedchem.4c00962

BibTeX
@article{Ong2024,
  author = {Ong, Han Wee and Yang, Xuan and Smith, Jeffery L and Dickmander, Rebekah J and Brown, Jason W and Havener, Tammy M and Taft-Benz, Sharon and Howell, Stefanie and Sanders, Marcia K and Capener, Jacob L and Couñago, Rafael M and Chang, Edcon and Krämer, Andreas and Moorman, Nathaniel J and Heise, Mark and Axtman, Alison D and Drewry, David H and Willson, Timothy M},
  title = {More than an Amide Bioisostere: Discovery of 1,2,4-Triazole-containing Pyrazolo[1,5- a ]pyrimidine Host CSNK2 Inhibitors for Combatting β-Coronavirus Replication},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {14},
  pages = {12261--12313},
  doi = {10.1021/acs.jmedchem.4c00962}
}
Kostenlos starten →